Retatrutide Dosage

In its clinical trials, retatrutide was given as a once-weekly subcutaneous injection whose dose was raised gradually over the first weeks of treatment. In the phase 2 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants started low and stepped up roughly every four weeks toward one of four weekly maintenance tiers — 1 mg, 4 mg, 8 mg or 12 mg — which they then held for the rest of a 48-week study. That is the whole of what the published dosing evidence describes.

There is no validated consumer or at-home retatrutide protocol. Retatrutide remains an investigational molecule, and the figures below are trial-design parameters reported here as research convention — not a personal dose, not a treatment plan, and not a recommendation to use any amount. This page answers the informational question, namely how retatrutide was dosed and escalated in studies, and is deliberately separate from the shop listings, which exist only to specify and supply the research compound. To see stocked formats and strengths, start at the retatrutide category hub; to understand the dosing evidence, read on.

How retatrutide was dosed in trials

Retatrutide is a single molecule that activates three receptors at once — GIP, GLP-1 and glucagon — which is why it is described as a triple agonist. Across the published obesity work it was administered once weekly by subcutaneous injection, the same cadence used for tirzepatide and semaglutide. The defining feature of the trial design was not the route but the gradual escalation: no one began at a high weekly dose. Instead the trial opened treatment at a low starting dose and increased it in steps.

The phase 2 obesity trial randomised adults to placebo or to retatrutide at weekly maintenance targets of 1 mg, 4 mg, 8 mg or 12 mg. For every arm assigned to 4 mg or more, treatment began at 2 mg or 4 mg per week and was raised about every four weeks until the assigned maintenance dose was reached — a titration window of up to roughly twelve weeks — after which the dose was held steady through the 48-week treatment period. The trial also compared the two starting doses (2 mg versus 4 mg) directly, which turned out to matter for tolerability, as covered below.

The phase 2 trial escalation schedule

The table shows a representative escalation to the top 12 mg maintenance tier, reconstructed from the trial's published design: a low start, four-week steps, and a held maintenance dose. The trial used more than one escalation regimen and the exact week boundaries are set out in the study's supplementary appendix, so treat the schedule as approximate. These are trial figures, not a recommended personal dose.

Trial period	Weekly subcutaneous dose (12 mg arm)	Purpose
Weeks 1–4	2 mg (starting dose)	Introduce the compound at the lowest step
Weeks 5–8	4 mg	First escalation
Weeks 9–12	8 mg	Second escalation
Week 13 onward	12 mg (maintenance)	Held to the end of the 48-week period

Arms assigned to a lower maintenance tier simply stopped climbing once they reached it: the 4 mg and 8 mg groups levelled off at 4 mg and 8 mg respectively, and the lowest arm stayed at 1 mg throughout. At the top of the range, the 12 mg maintenance dose produced the largest mean body-weight reduction in the trial — on the order of 24% at 48 weeks — while placebo changed little. Those outcome figures describe the study population as a whole; they are not a result you should expect, nor a reason to target any particular dose.

Why the dose is escalated: GI tolerability

The reason for stepping up slowly is gastrointestinal tolerability. Like other gut-hormone agonists, retatrutide's most commonly reported adverse events in the trial were gastrointestinal — nausea, diarrhoea, vomiting and constipation — and these were most frequent while the dose was rising. Escalation exists to give that tolerance time to build. The trial's direct comparison of starting doses made the point concretely: beginning at 4 mg per week produced more gastrointestinal events than beginning at 2 mg, which is why a lower, slower start is the pattern the study data support. Most reported events were mild to moderate.

Reconstitution and draw volume

Retatrutide supplied as a lyophilised (freeze-dried) vial is a powder, not a ready-to-use liquid, so it must be reconstituted with bacteriostatic water before any volume can be drawn. The concept is simple, but the arithmetic is where mistakes happen: the amount of water you add sets the concentration, and the concentration decides how many units on the syringe correspond to a given milligram figure. Add more water and each unit carries less peptide; add less and each unit carries more.

Do the maths before you touch the vial. Our peptide reconstitution calculator is the core companion to this guide: enter the vial strength, the water volume and your target amount, and it returns the draw volume on a standard insulin syringe. Use it for both the HD Labs Retatrutide 32 vial and the smaller HD Labs Retatrutide 10 vial so the concentration you prepare matches the schedule you are studying. We give the concept here, not a personal dose — what you draw is a decision for a qualified professional, not for this page.

Storage

Retatrutide is temperature-sensitive. As a general handling matter, the lyophilised powder is kept refrigerated at about 2–8 °C and protected from light and freezing; once reconstituted, the solution is also refrigerated and used within a limited window rather than stored indefinitely. BeSkinny ships temperature-sensitive peptides cold-chain with gel packs to preserve integrity in transit across South Africa. Always defer to the certificate of analysis and any handling notes supplied with your specific batch, which take precedence over general guidance.

What affects tolerability

Several factors shape how the reported tolerability pattern plays out in the trial data:

• Starting dose. A 2 mg start was associated with fewer gastrointestinal events than a 4 mg start.
• Speed of escalation. Longer intervals between steps give tolerance more time to develop; the trial stepped up roughly every four weeks.
• Maintenance tier. Higher weekly targets carry a heavier burden of the same class effects, so the 12 mg arm sat at the top of both the efficacy and the side-effect range.
• Individual variation. Trial averages hide wide person-to-person differences; group data cannot predict any individual response.

Because these factors interact, the escalation schedule is best read as a tolerability tool from the study design rather than a number to copy. For the broader safety picture across peptides, see are peptides safe?, and for how the triple agonist compares with the dual agonist, see retatrutide vs tirzepatide.

Research-use and medical disclaimer

Everything on this page is provided strictly for laboratory and research reference. It is not medical advice, not prescribing advice, and not a human dosing protocol. The doses, escalation steps and outcome figures describe what a published clinical trial reported, cited following standard research-reference convention; they are not instructions, and they are not a validated consumer protocol, which does not exist for retatrutide. Retatrutide is an investigational molecule that has not completed the approval process, and BeSkinny supplies it as a research compound only. Before making any decision about a gut-hormone agonist, consult a registered healthcare professional who can account for your individual circumstances. Nothing here replaces that conversation.

Frequently asked questions

How much retatrutide was used per week in trials?

In the phase 2 obesity trial, weekly maintenance doses were 1 mg, 4 mg, 8 mg or 12 mg, reached by starting low (2 mg or 4 mg) and escalating about every four weeks. These are trial figures for a 48-week study, not a recommended personal dose. What is appropriate for any individual is a question for a qualified healthcare professional.

How do you reconstitute retatrutide?

A lyophilised vial is a freeze-dried powder that must be dissolved in bacteriostatic water before any dose can be drawn. The water volume you add sets the concentration and therefore the number of syringe units per milligram. Work the numbers out first with the peptide reconstitution calculator; this page explains the concept, not a personal dose.

Why start on a low dose?

To manage gastrointestinal tolerability. Nausea, diarrhoea, vomiting and constipation were the most commonly reported events in the trial and were most frequent while the dose was rising. Starting low and stepping up gives that tolerance time to build; in the trial, a 2 mg start produced fewer such events than a 4 mg start.

How long did titration take?

In the trial, escalation ran about every four weeks for up to roughly twelve weeks until the assigned maintenance dose was reached, after which the dose was held for the remainder of the 48-week treatment period. Lower-target arms reached their maintenance tier sooner because they had fewer steps to climb.

Is there an approved retatrutide dose?

No. Retatrutide is investigational and has no validated consumer protocol; the only dosing figures that exist are trial-design parameters like those above. Any real-world decision belongs with a registered healthcare professional, not with a web page.

Sources

• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. NEJM and PubMed
• Eli Lilly and Company. Phase 2 retatrutide results published in the New England Journal of Medicine (investor release, 2023). investor.lilly.com
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity (NCT04881760). clinicaltrials.gov
• Drugs.com. Retatrutide — investigational drug monograph. drugs.com